Nyrada Inc
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WANyrada Inc (NYR) is a preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. It focuses on areas of substantial unmet clinical need and has identified drug candidates with therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist. It currently has three wholly-owned drug programs:
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 20th | Nyrada Inc | 445% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Nyrada Inc | $3.2m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEWS: Tagged in Hydration rehydrates share price with non-US asset sale | 04 Oct 2024 |
| NEW ROLE: Gisela Mautner, Non-Executive Director | 07 Aug 2024 |
| NEWS: Tagged in Calendar quirk sees great leap for top ASX runner | 01 Mar 2024 |
| NEW ROLE: Marcus Frampton, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: David Franks, Company Secretary | 03 Nov 2020 |
| NEW ROLE: James Bonnar, Chief Executive Officer | 03 Nov 2020 |
| NEW ROLE: Peter Marks, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Ian Dixon, Founder, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: John A Moore, Non-Executive Chairman, Non-Executive Director | 03 Nov 2020 |
